Mucin 1 (MUC1) is a transmembrane glycoprotein overexpressed in several cancer cells in which it regulates cell surface properties, tumor invasion, and cell death. Recently, we reported that MUC1-C, the C-terminal subunit of MUC1, is involved in the growth of mouse embryonic stem (ES) cells. However, the functional significance of MUC1-C in human ES cells remains unclear. In this study, we investigated the expression and function of MUC1-C in human ES cells. Based on reverse transcription-polymerase chain reaction, western blotting, and confocal microscopy following immunostaining, undifferentiated human ES cells expressed MUC1-C and the expression level decreased during differentiation. Inhibition of MUC1-C, by the peptide inhibitor GO201 that targets the cytoplasmic domain of MUC1-C (MUC1-CD), reduced cell proliferation and OCT4 protein expression, and promoted cell death. Moreover, the inhibition of MUC1-C increased the intracellular reactive oxygen species (ROS) levels and downregulated expression of glycolysis-related enzymes. These findings indicate that expression and function of MUC1-C are required for stem cell properties involved in cell proliferation, maintenance of pluripotency and optimal ROS levels, and a high glycolytic flux in human ES cells. In addition, forced overexpression of MUC1-CD increased the efficiency of reprogramming from fibroblast cells to induced pluripotent stem cells, suggesting that MUC1-C expression can contribute to the reprogramming process.
Get full access to this article
View all access options for this article.
References
1.
HollingsworthMA and SwansonBJ. (2004). Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer, 4:45–60.
2.
LevitinF, SternO, WeissM, Gil-HennC, ZivR, ProkocimerZ, SmorodinskyNI, RubinsteinDB and WreschnerDH. (2005). The MUC1 SEA module is a self-cleaving domain. J Biol Chem, 280:33374–33386.
3.
Kufe DW. (2013). MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene, 32:1073–1081.
4.
NathS and MukherjeeP. (2014). MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med, 20:332–342.
5.
LengY, CaoC, RenJ, HuangL, ChenD, ItoM and KufeD. (2007). Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem, 282:19321–19330.
6.
AhmadR, RajabiH, KosugiM, JoshiMD, AlamM, VasirB, KawanoT, KharbandaS and KufeD. (2011). MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal, 4:ra9.
7.
HuangL, ChenD, LiuD, YinL, KharbandaS and KufeD. (2005). Muc1 oncoprotein blocks glycogen synthase kinase 3β–Mediated phosphorylation and degradation of β-catenin. Cancer Res, 65:10413–10422.
8.
RainaD, KharbandaS and KufeD. (2004). The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem, 279:20607–20612.
9.
LiQ, KuwaharaH, YinL, LiY, RenJ, KufeD, YuW and Carraway IIIKL. (2001). The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and β-catenin. J Biol Chem, 276:35239–35242.
10.
Kufe DW. (2009). Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther, 8:1197–1203.
11.
LiW, ZhangN, JinC, LongMD, RajabiH, YasumizuY, FushimiA, YamashitaN, HagiwaraM and ZhengR. (2020). MUC1-C drives stemness in progression of colitis to colorectal cancer. JCI insight, 5:137112.
MehlaK and SinghPK. (2014). MUC1: a novel metabolic master regulator. Biochim Biophys Acta, 1845:126–135.
14.
EvansMJ and KaufmanMH. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature, 292:154–156.
15.
XuX, DuanS, YiF, OcampoA, LiuG and BelmonteJCI. (2013). Mitochondrial regulation in pluripotent stem cells. Cell Metab, 18:325–332.
16.
LiuG, DavidBT, TrawczynskiM and FesslerRG. (2020). Advances in pluripotent stem cells: history, mechanisms, technologies, and applications. Stem Cell Rev Rep, 16:3–32.
17.
OhS, LeeCK, ChoKJ, LeeK, ChoS and HongS. (2012). Technological progress in generation of induced pluripotent stem cells for clinical applications. Sci World J, 2012:417809.
18.
Al AbbarA, NgaiSC, NogralesN, AlhajiSY and AbdullahS. (2020). Induced pluripotent stem cells: reprogramming platforms and applications in cell replacement therapy. Biores Open Access, 9:121–136.
19.
ParkJ, ParkS, ChoiJ, HanM and LeeY. (2021). Inhibition of MUC1-C increases ROS and cell death in mouse embryonic stem cells. Int J Stem Cells, 14:180–190.
20.
KangH, KimY, KwonH, SokD and LeeY. (2007). Enhancement of NF-κ B expression and activity upon differentiation of human embryonic stem cell line SNUhES3. Stem Cells Dev, 16:615–624.
21.
RainaD, AhmadR, JoshiMD, YinL, WuZ, KawanoT, VasirB, AviganD, KharbandaS and KufeD. (2009). Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res, 69:5133–5141.
22.
ParkJ, KimY, HaY, KwonH and LeeY. (2012). High sensitivity of embryonic stem cells to proteasome inhibitors correlates with low expression of heat shock protein and decrease of pluripotent cell marker expression. BMB Rep, 45:299–304.
23.
KimY, ParkJ, HaY, ParkS, KimHS, OhSK and LeeY. (2012). Chromosomal modification in human embryonic stem cells cultured in a feeder-free condition after single cell dissociation using accutase. Dev Reprod, 16:353–361.
24.
ParkS, ParkJ, YooH, ParkH and LeeY. (2017). Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells. Redox Biol, 13:470–476.
25.
Orozco-FuentesS, NeganovaI, WadkinLE, BaggaleyAW, BarrioRA, LakoM, ShukurovA and ParkerNG. (2019). Quantification of the morphological characteristics of hESC colonies. Sci Rep, 9:17569.
26.
FusakiN, BanH, NishiyamaA, SaekiK and HasegawaM. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci, 85:348–362.
27.
JonckheereN and Van SeuningenI. (2010). The membrane-bound mucins: from cell signalling to transcriptional regulation and expression in epithelial cancers. Biochimie, 92:1–11.
28.
HikitaST, KosikKS, CleggDO and BamdadC. (2008). MUC1* mediates the growth of human pluripotent stem cells. PLoS One, 3:e3312.
29.
SmaggheBJ, StewartAK, CarterMG, SheltonLM, BernierKJ, HartmanEJ, CalhounAK, HatziioannouVM, LillacciG and KirkBA. (2013). MUC1* ligand, NM23-H1, is a novel growth factor that maintains human stem cells in a more naïve state. PLoS One, 8:e58601.
30.
HataT, RajabiH, TakahashiH, YasumizuY, LiW, JinC, LongMD, HuQ, LiuS and FushimiA. (2019). MUC1-C activates the NuRD complex to drive dedifferentiation of triple-negative breast cancer cells. Cancer Res, 79:5711–5722.
31.
YinL, HuangL and KufeD. (2004). MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem, 279:45721–45727.
32.
WeiX, XuH and KufeD. (2005). Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell, 7:167–178.
33.
YinL, KharbandaS and KufeD. (2009). MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. Int J Oncol, 34:1691–1699.
34.
YinL, KosugiM and KufeD. (2012). Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood, 119:810–816.
35.
YinL, LiY, RenJ, KuwaharaH and KufeD. (2003). Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem, 278:35458–35464.
36.
FolmesCD and TerzicA. (2016). Energy metabolism in the acquisition and maintenance of stemness. Semin Cell Dev Biol, 52:68–75.
37.
ChaikaNV, GebregiworgisT, LewallenME, PurohitV, RadhakrishnanP, LiuX, ZhangB, MehlaK, BrownRB and CaffreyT. (2012). MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci U S A, 109:13787–13792.
38.
KosugiM, AhmadR, AlamM, UchidaY and KufeD. (2011). MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells. PLoS One, 6:e28234.
39.
MoraA, KomanderD, van AaltenDM and AlessiDR. (2004). PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol, 15:161–170.
40.
WangXQ, LoCM, ChenL, NganES, XuA and PoonRY. (2017). CDK1-PDK1-PI3K/Akt signaling pathway regulates embryonic and induced pluripotency. Cell Death Differ, 24:38–48.
41.
MazurekS. (2011). Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol, 43:969–980.
42.
ChristensenDR, CalderPC and HoughtonFD. (2015). GLUT3 and PKM2 regulate OCT4 expression and support the hypoxic culture of human embryonic stem cells. Sci Rep, 5:17500.
43.
Carson DD. (2008). The cytoplasmic tail of MUC1: a very busy place. Sci Signal, 1:pe35.
44.
RuizS, PanopoulosAD, HerreríasA, BissigK, LutzM, BerggrenWT, VermaIM and BelmonteJCI. (2011). A high proliferation rate is required for cell reprogramming and maintenance of human embryonic stem cell identity. Curr Biol, 21:45–52.
45.
LevensteinME, LudwigTE, XuR, LlanasRA, VanDenHeuvel-KramerK, ManningD and ThomsonJA. (2006). Basic fibroblast growth factor support of human embryonic stem cell self-renewal. Stem Cells, 24:568–574.
46.
SchnerchA, CerdanC and BhatiaM. (2010). Distinguishing between mouse and human pluripotent stem cell regulation: the best laid plans of mice and men. Stem Cells, 28:419–430.
47.
NiwaH, BurdonT, ChambersI and SmithA. (1998). Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev, 12:2048–2060.
48.
GinisI, LuoY, MiuraT, ThiesS, BrandenbergerR, Gerecht-NirS, AmitM, HokeA, CarpenterMK and Itskovitz-EldorJ. (2004). Differences between human and mouse embryonic stem cells. Dev Biol, 269:360–380.
49.
PadgettJ and SantosSD. (2020). From clocks to dominoes: lessons on cell cycle remodelling from embryonic stem cells. FEBS Lett, 594:2031–2045.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
